LIFEVANTAGE CORP Revenue Recognition, Sales Returns, Reserve for Sales Returns
LIFEVANTAGE CORP (LFVN) reported Revenue Recognition, Sales Returns, Reserve for Sales Returns of $400.00 thousand for the 12-month period ending 2019-06-30, per its 10-K filed 2019-08-14.
Discontinued › Notes › ASU 2014-09 Transition
us-gaap:RevenueRecognitionSalesReturnsReserveForSalesReturns · last filed 2019-08-14
- LIFEVANTAGE CORP revenue recognition, sales returns, reserve for sales returns for fiscal 2019 was $400.00K, a 0.00% change from fiscal 2018.
- LIFEVANTAGE CORP revenue recognition, sales returns, reserve for sales returns for fiscal 2018 was $400.00K, a 0.00% change from fiscal 2017.
- LIFEVANTAGE CORP revenue recognition, sales returns, reserve for sales returns for fiscal 2017 was $400.00K, a 33.33% increase from fiscal 2016.
- LIFEVANTAGE CORP revenue recognition, sales returns, reserve for sales returns for fiscal 2016 was $300.00K, a 200.00% increase from fiscal 2015.
| Period end | Revenue Recognition, Sales Returns, Reserve for Sales Returns 12 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 12 month as first filed |
|---|---|---|
| 2019-06-30 | $400.00K 10-K · filed 2019-08-14 | |
| 2018-06-30 | $400.00K 10-K · filed 2019-08-14 | |
| 2017-06-30 | $400.00K 10-K · filed 2018-08-15 | |
| 2016-06-30 | $300.00K 10-K · filed 2017-09-07 | |
| 2015-06-30 | $100.00K 10-K · filed 2016-12-12 | |
| 2014-06-30 | $600.00K 10-K · filed 2015-09-01 | |
| 2013-06-30 | $600.00K 10-K · filed 2014-09-10 | |
| 2012-06-30 | $900.00K 10-K · filed 2013-09-12 | $862.60K 10-K · filed 2012-09-10 |
| 2011-06-30 | $435.13K 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |